Somatostatin Receptor Imaging in NPC, EBV Related Cancers
Somatostatin Receptor Imaging in Nasopharyngeal Cancer, Epstein-Barr Virus (EBV) Related Cancers and Other Rare Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Wen Long Nei, MD
- Phone Number: +65 6436 8000
- Email: nei.wen.long@singhealth.com.sg
Study Locations
-
-
-
Singapore, Singapore
- National Cancer Centre Singapore
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Locally advanced, metastatic or locally recurrent NPC that are going for FDG PET as part of their investigations
- Patients that have gone for Ga-68 DOTATATE imaging before are eligible for repeat imaging
- Histologically confirmed NPC
- Above 21 years of age
Exclusion Criteria:
- Patients below 21 years of age
- Pregnant and breast feeding ladies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: PET imaging
|
Patients will be fasted for 6 hours prior to intravenous injection of 370MBq +/- 10% (18)F-fluorodeoxyglucose.
Scanning will be performed at an interval of at least 60 minutes following the injection.
200MBq +/- 10% Galium-68 DOTATATE will be injected intravenously.
Scanning will be performed approximately 60 minutes after the injection.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Amount of tracer uptake in the tumour lesions of NPC patients
Time Frame: From time of tracer injection to time the scan is performed
|
The maximum standardized uptake values (SUVmax) will be measured.
If the average SUVmax of all the lesions is more than 10, the patient will be considered to have an overall high somatostatin receptor density.
|
From time of tracer injection to time the scan is performed
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Amount of tracer uptake in the tumour lesions of patients with EBV related cancers
Time Frame: From time of tracer injection to time the scan is performed
|
The maximum standardized uptake values (SUVmax) will be measured.
If the average SUVmax of all the lesions is more than 10, the patient will be considered to have an overall high somatostatin receptor density.
|
From time of tracer injection to time the scan is performed
|
|
Number of somatostatin receptors in patient biopsy samples
Time Frame: Upon signing the informed consent form
|
Upon signing the informed consent form
|
|
|
Amount of somatostatin circulating tumour cells in patient blood samples
Time Frame: At the time of scan
|
At the time of scan
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Wen Long Nei, MD, National Cancer Centre, Singapore
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Stomatognathic Diseases
- Neoplasms by Site
- Neoplasms
- Infections
- Virus Diseases
- Neoplasms by Histologic Type
- Head and Neck Neoplasms
- Neoplasms, Glandular and Epithelial
- DNA Virus Infections
- Carcinoma
- Otorhinolaryngologic Diseases
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Nasopharyngeal Diseases
- Pharyngeal Diseases
- Herpesviridae Infections
- Tumor Virus Infections
- Nasopharyngeal Carcinoma
- Nasopharyngeal Neoplasms
- Epstein-Barr Virus Infections
Other Study ID Numbers
Other Study ID Numbers
- NPC EBV SSTR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.